Chris Hill
@dochill1982.bsky.social
๐ค 463
๐ฅ 43
๐ 33
Nephrologist. Liverpool FC, cricket and Test Match Special fan. Proud dad of Lucy and Rose
reposted by
Chris Hill
American Journal of Kidney Diseases
21 days ago
The Roles of A Proliferation-Inducing Ligand (APRIL) and B-Cell Activating Factor (BAFF) in IgA Nephropathy
bit.ly/4rs0u1r
0
1
1
@askrenal.bsky.social
anyone in England/Scotland/Wales - do you have to dispense Kinpeygo and Sparsentan direct from hospital pharmacy or is it available via community pharmacy? In NI we have to dispense direct from hospital due to an issue about cost parity in primary care.
24 days ago
0
0
0
Looking forward to our March teaching session for neph trainees in NI! Itโs all about the
#NephMadness
!
add a skeleton here at some point
27 days ago
0
3
1
reposted by
Chris Hill
JAMA
28 days ago
IgA nephropathy is the most common cause of immune-mediated glomerular disease worldwide. ๐ This Review summarizes the pathophysiology, epidemiology, clinical presentation, diagnosis, treatment, and prognosis of primary IgA nephropathy in adults.
ja.ma/47bIhht
0
5
6
reposted by
Chris Hill
Swapnil Hiremath ๐๐จ๐ฆ
about 1 month ago
This week we discuss the 2026 KDIGO anemia guidelines on
#NephJC
Read our deep dive into the data here
www.nephjc.com/news/kdigo-a...
loading . . .
2026 KDIGO Anemia Management Guidelines โ NephJC
This week, we will discuss 2026 KDIGO anemia management in patients with kidney disease
https://www.nephjc.com/news/kdigo-anemia
1
9
4
reposted by
Chris Hill
Edgar V. Lerma ๐ต๐ญ
about 1 month ago
Real-World Hospitalization Outcomes with On-Line Hemodiafiltration Versus High-Flux Hemodialysis ca. 2025 from
@asnpublications.bsky.social
#Nephpearls
#NephSky
#VisualAbstract
by
@husamjz.bsky.social
๐
pubmed.ncbi.nlm.nih.gov/41433104/
1
4
5
#askrenal
@nephjc.bsky.social
have a young male with multisystem sarcoid. Eyes, liver, hilar LNs and interstitial nephritis. Granulomas so big you could pick them out without magnification on histo slide! Any experience of anti TNF as steroid sparing for renal involvement?
about 1 month ago
1
2
2
reposted by
Chris Hill
about 2 months ago
A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment in IgA nephropathy
#nephsky
loading . . .
A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment in IgA nephropathy
Corticosteroids are effective for treating IgA nephropathy but have important adverse effects. In this secondary analysis of the TESTING cohort, we generated a model to predicts, for an individualโฆ
https://buff.ly/89HjdYe
0
2
4
reposted by
Chris Hill
American Journal of Kidney Diseases
about 2 months ago
Exercise and Kidney Health: Core Curriculum 2026
bit.ly/3YK6uXv
(OPEN ACCESS)
0
3
4
reposted by
Chris Hill
2 months ago
Systematic Review of Efficacy and Safety of #Avacopan in #RealWorld Clinical Practice #VisualAbstract by @Cteodosiu
https://www.kireports.org/article/S2468-0249(25)00771-5/fulltext
0
1
1
reposted by
Chris Hill
Lupus UK
2 months ago
NICE have recommended that a new treatment, obinutuzumab, can be used in combination with mycophenolate mofetil (MMF) to treat some patients with lupus nephritis in the NHS in England and Wales.ย ๐ Learn more at https://lupusuk.org.uk/latest-news/
#Lupus
#LupusNephritis
#Obinutuzumab
0
2
2
reposted by
Chris Hill
NEJM.org
3 months ago
PISCES trial: More than two thirds of patients receiving hemodialysis for end-stage kidney disease are affected by cardiovascular disease. Research findings on fish-oil supplementation in patients treated with hemodialysis are summarized in a new Quick Take video.
nej.md/3YsyWx2
#MedSky
0
7
1
View from the office this morning. Sunrise over
#Belfast
3 months ago
0
1
0
@leannestratton.bsky.social
one for you
add a skeleton here at some point
4 months ago
0
1
0
reposted by
Chris Hill
American Journal of Kidney Diseases
4 months ago
Quantifying APOL1, Human Leukocyte Antigen, and Other Genetic Contributions to Unexplained Kidney Failure
#OpenAccess
bit.ly/4nfGoXe
0
3
1
reposted by
Chris Hill
5 months ago
#Delphi Consensus on Surrogate Endpoints in #C3G and Primary #ICMPGN #VisualAbstract by
Jade Teakell, MD
https://www.kireports.org/article/S2468-0249(25)00672-2/fulltext
0
4
3
Wonder what it would be like in a head to head with obinutuzumab? Used it successfully for first time recently in young male with min change who didnโt respond to ritux
add a skeleton here at some point
5 months ago
0
2
0
reposted by
Chris Hill
Joel Topf
5 months ago
Simultaneous publication in the NEJM
#KidneyWk
www.nejm.org/doi/full/10....
loading . . .
Sibeprenlimab in IgA Nephropathy โ Interim Analysis of a Phase 3 Trial | NEJM
The cytokine A proliferation-inducing ligand (APRIL) is considered a key driver of the pathogenesis of IgA nephropathy. Sibeprenlimab, a humanized IgG2 monoclonal antibody, selectively binds to and...
https://www.nejm.org/doi/full/10.1056/NEJMoa2512133?utm_source=conf&utm_medium=qr&utm_campaign=ASN2025
0
3
2
reposted by
Chris Hill
Swapnil Hiremath ๐๐จ๐ฆ
5 months ago
And another ns-MRA Balcinrenone added to Dapa in proteinuric CKD
#KidneyWK
@thelancet.com
www.thelancet.com/journals/lan...
loading . . .
Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinica...
In participants with chronic kidney disease at increased risk of disease progression, a fixed dose combination of balcinrenone and dapagliflozin was superior to dapagliflozin alone in reducing albumin...
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02014-8/abstract
0
12
7
After all the fancy new medications weโve tried in HD to improve prognosisโฆ We should just have given them cod liver oil!
#KidneyWk
#nephjc
add a skeleton here at some point
5 months ago
0
2
0
reposted by
Chris Hill
NEJM.org
5 months ago
In the PISCES trial involving participants receiving hemodialysis, fish oil (nโ3 fatty acids) was compared with corn-oil placebo. The rate of serious cardiovascular events was lower with daily fish-oil supplementation. Full trial results:
nej.md/49zWuqo
@asnkidney.bsky.social
|
#KidneyWk
2
25
17
reposted by
Chris Hill
ASN Publications
5 months ago
Now live in #ASNJASN, simultaneously published with #KidneyWk: "Immunosuppression in Older Kidney Transplant Recipients: A Randomized Controlled Trial" Read more:
kidney.pub/JASN0924
1
6
6
reposted by
Chris Hill
5 months ago
#Infliximab for Grade III/IV #ICI #Nephritis Clinical and Translational Evidence #VisualAbstract by
Edgar V. Lerma ๐ต๐ญ
https://www.kireports.org/article/S2468-0249(25)00662-X/fulltext
0
4
3
reposted by
Chris Hill
NEJM.org
5 months ago
ORIGIN phase 3 trial: In an interim analysis of a clinical trial, atacicept, a fusion protein that binds and inhibits two cytokines thought to be central to the pathophysiology of IgA nephropathy, significantly reduced proteinuria.
nej.md/3JEq8QL
@asnkidney.bsky.social
|
#KidneyWk
0
18
10
reposted by
Chris Hill
josh farkas ๐
5 months ago
The BICAR-ICU-2 trial just dropped! RCT involving IV bicarb in metabolic acidosis among patients with mod-severe AKI Bicarb didn't affect mortality but it reduced the need for dialysis & risk of bacteremia VERY similar conclusions to BICAR-ICU-1 ๐งต #1/
jamanetwork.com/journals/jam...
#EMIMCC
2
46
26
reposted by
Chris Hill
Nephrology Journal Club
5 months ago
Last
#NephJC
short on individual data meta-analysis showing that although we love flozins for their extensive benefits we actually donโt completely understand how they work
#Nephsky
โ๏ธMeta by
@willkidney.bsky.social
& co ๐ Write up by
@nephroseeker.medsky.social
www.nephjc.com/news/2025/10...
loading . . .
Empagliflozin, the kidney, and what we still donโt understand โ NephJC
NephJC short on an empagliflozin meta-analysis
http://www.nephjc.com/news/2025/10/20/empa-ma
1
10
7
Curious to know what North American folks think about whether a drop in BP will be enough to get Baxdrostat licensed? In UK suspect NICE will want to see MACE data first to do cost-effectiveness analysis.
#medsky
#askrenal
#nephjc
loading . . .
Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension | NEJM
Aldosterone dysregulation plays an important pathogenic role in hard-to-control hypertension. In several studies, baxdrostat, an aldosterone synthase inhibitor, reduced the seated systolic blood pr...
https://www.nejm.org/doi/full/10.1056/NEJMoa2507109
6 months ago
1
4
3
One for you
@leannestratton.bsky.social
add a skeleton here at some point
6 months ago
0
1
0
reposted by
Chris Hill
UK Kidney Association
6 months ago
๐ Your first chance to register for
#UKKW26
& preview the draft programme is coming on Monday ๐ Join us in spa town, Harrogate, this March for cutting-edge
#KidneyCare
symposia, lectures & workshops. ๐ก Early bird registration = 10% savings!
#KidneyProfessionals
#KidneyHealth
#KidneyEducation
0
0
2
Iptacopan for C3G is published. Currently going through NICE appraisal in UK
loading . . .
Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study
Iptacopan showed a statistically significant, clinically meaningful proteinuria reduction in addition to RAAS inhibitors and immunosuppression at 6 months. Iptacopan was well tolerated with an accepta...
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01148-1/fulltext
6 months ago
0
1
0
reposted by
Chris Hill
Nayan Arora
6 months ago
Interesting diuretic resistance study. Adunctive thiazides take the lead over loop intensification? Nice discussion on mechanisms of DR, both practical and hypothetical.
#nephsky
journals.lww.com/jasn/abstrac...
loading . . .
Loop Diuretic Dose Intensification versus Adjuvant Thiazide ... : Journal of the American Society of Nephrology
g diuretic resistance mechanism could optimize diuretic response. Methods: Patients hospitalized with heart failure and diuretic resistance (6-hour cumulative natriuresis <100 mmol after IV loop di...
https://journals.lww.com/jasn/abstract/9900/loop_diuretic_dose_intensification_versus_adjuvant.772.aspx
0
9
5
www.nejm.org/doi/full/10....
Completely non-nephrology post but pretty cool that old fashioned aspirin cuts recurrence risk by half in certain bowel cancers
loading . . .
Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer | NEJM
Aspirin reduces the incidence of colorectal adenoma and colorectal cancer among high-risk persons. Observational studies suggest that aspirin may also improve disease-free survival after diagnosis,...
https://www.nejm.org/doi/full/10.1056/NEJMoa2504650
6 months ago
0
3
0
Another new drug for IgA with the potential for major disease modifying effect!
add a skeleton here at some point
6 months ago
1
5
1
reposted by
Chris Hill
ISNkidneycare
6 months ago
โก๏ธ Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Assessing the Efficacy and Safety of Felzartamab for IgA Nephropathy
www.kidney-internati...
1
7
7
reposted by
Chris Hill
Joel Topf
6 months ago
GLP1ra in ADPKD?
pubmed.ncbi.nlm.nih.gov/40815122/
loading . . .
GLP-1RA Semaglutide Delays the Progression of ADPKD Through Regulation of Glycolysis, Mitochondria Function and Ketosis - PubMed
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease that is caused by mutations in PKD genes. Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are a class of medicati...
https://pubmed.ncbi.nlm.nih.gov/40815122/
3
14
7
reposted by
Chris Hill
Swapnil Hiremath ๐๐จ๐ฆ
7 months ago
Not just for albuminuria - flozination and co sequent glycosuria can result in interference for other biomarkers too Albuminuria data:
pubmed.ncbi.nlm.nih.gov/36736537/
add a skeleton here at some point
0
5
4
reposted by
Chris Hill
Swapnil Hiremath ๐๐จ๐ฆ
8 months ago
Paired nicely with the French ALCHEMIST trial (also negative)
www.thelancet.com/journals/lan...
#NephJC
#NephSky
loading . . .
Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-anal...
In patients with kidney failure on haemodialysis and with high risk of adverse cardiovascular outcomes, spironolactone did not reduce the incidence of major cardiovascular events. The updated meta-ana...
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01194-8/abstract?rss=yes
1
9
2
reposted by
Chris Hill
Swapnil Hiremath ๐๐จ๐ฆ
8 months ago
Spironolactone does not work for dialysis ACHIEVE published in
@thelancet.com
@lastwalsh.bsky.social
and colleagues
www.thelancet.com/journals/lan...
Coming soon to a
#NephJC
near you
loading . . .
Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial
Among patients receiving maintenance dialysis, spironolactone 25 mg daily orally did not reduce the composite outcome of cardiovascular mortality and hospitalisation due to heart failure compared with...
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01198-5/fulltext?rss=yes
5
31
19
reposted by
Chris Hill
ISNkidneycare
8 months ago
And commentary: Anti-rituximab Antibodies in Primary Membranous Nephropathy: Time for Routine Monitoring in Clinical Practice?
loading . . .
Anti-Rituximab Antibodies in Primary Membranous Nephropathy: Time for Routine Monitoring in Clinical Practice?
Rituximab, a chimeric monoclonal antibody that targets the CD20 molecule on the surface of B cells, has been part of the therapeutic armamentarium for glomerular diseases since the early 2000s. Over the past decade, it has emerged as a standard-of-care treatment for primary membranous nephropathy (MN) (pMN) and is being increasingly used in steroid-dependent nephrotic syndrome for both pediatric and adult patients.1 The relapsing nature of these renal diseases may require repeated cycles of rituximab to achieve and maintain remission.
https://www.kireports.org/article/S2468-0249(25)00405-X/fulltext
0
0
1
reposted by
Chris Hill
Nephrology Times
8 months ago
โ ๏ธ The FDA has approved pegcetacoplan (Empaveli) for treating C3G and IC-MPGN.
#kidneydisease
#nephrology
#nephsky
#c3g
www.docwirenews.com/post/fda-app...
loading . . .
FDA Approves Pegcetacoplan for C3G and IC-MPGN | Docwire News
The FDA approved pegcetacoplan for treating C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN in patients age 12 and older.
https://www.docwirenews.com/post/fda-approves-pegcetacoplan-for-c3g-and-ic-mpgn
0
9
7
reposted by
Chris Hill
Critical Care Reviews
8 months ago
The Role of Chloride in Cardiorenal Syndrome: A Practical Review CCR Journal Watch - tracking the critical care literature daily
https://criticalcarereviews.com/latest-evidence/journal-watch
0
0
1
reposted by
Chris Hill
Brendon Neuen
9 months ago
SGLT2i in CKD: impact beyond kidneys ๐ป 15% all-cause hospitalizations โ Consistent regardless of eGFR, UACR & diabetes ๐ฅ ~36 fewer hospitalizations per 1000 pt-years Large absolute gains for patients & health systems Meta-analysis in
@asnpublications.bsky.social
journals.lww.com/cjasn/pages/...
1
13
10
reposted by
Chris Hill
NEJM.org
9 months ago
In 15 patients with primary aldosteronism, baxdrostat (a second-generation, nonimidazole aldosterone synthase inhibitor) resolved or reduced the severity of hypertension, excessive aldosterone production, and hypokalemia. Full SPARK study results:
nej.md/40Js1kz
#ENDO2025
0
29
15
Weโre under way recruiting for the Phase 3 in Northern Ireland!
add a skeleton here at some point
9 months ago
0
3
0
reposted by
Chris Hill
Swapnil Hiremath ๐๐จ๐ฆ
9 months ago
A medical adrenalectomy? ASIs advance - Baxdrostat in primary aldosteronism now
www.nejm.org/doi/full/10....
n = 15 single arm trial from
@adinaturcu.bsky.social
and
@astra-zeneca.bsky.social
in
@nejm.org
~ 25/10 mm Hg BP lowering and impressive aldosterone level drop
#Hypertension
#EndoSky
0
23
12
reposted by
Chris Hill
Nephrology Journal Club
9 months ago
CAPTIVATE= phase 3, adaptive, platform RCT
#NephTrials
#NephJC
๐ฏ Find the best treatment, or combo, that ๐ CKD progression โ๏ธBlog
@nephroseeker.medsky.social
@sayalibthakare.bsky.social
โช
@dramiliflores.bsky.social
Reviewed by
@hswapnil.medsky.social
, S. Kotwal
www.nephjc.com/news/nephtri...
loading . . .
From single shots to strategy: How CAPTIVATE is reframingย the NephTrials playbook โ NephJC
Summary of the CAPTIVATE platform which will be a twitter spaces discussion
https://www.nephjc.com/news/nephtrials-captivate
0
4
5
reposted by
Chris Hill
NEJM.org
9 months ago
Presented at the
#ADASciSessions
: The MariTide phase 2 trial of once-monthly maridebart cafraglutide, a peptideโantibody conjugate, showed substantial weight reduction in participants with obesity with or without type 2 diabetes. Full trial results:
nej.md/3ZHxLeb
0
4
3
reposted by
Chris Hill
Swapnil Hiremath ๐๐จ๐ฆ
9 months ago
GLP1RA in kidney transplant recipients Retrospective study from
@thelancetendo.bsky.social
Sadly $gated
www.thelancet.com/journals/lan...
Canโt accept the huge benefit - likely selection bias in who gets it, but no signal of clear harm. Need more data on possible absorption woes, GI issues
loading . . .
GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study
GLP-1 receptor agonists were associated with better graft and patient survival. Clinical trials are needed to confirm these findings.
https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00371-1/abstract
1
12
2
Seems like iv hydrocortisone might save a few CVVH filters or sessions of HD in septic shock.
#nephjc
#nephsky
#CCR25
add a skeleton here at some point
10 months ago
1
14
5
reposted by
Chris Hill
JAMA Network Open
10 months ago
Intravenous hydrocortisone was associated with a reduced need for new kidney replacement therapy in patients with septic shock.
#CCR25
#MedSky
ja.ma/3SLC3xg
3
19
11
Load more
feeds!
log in